Opinion statement
Juvenile myelomonocytic leukemia is an aggressive neoplasia of early childhood. Only allogeneic stem cell transplantation (SCT) offers a long-term cure. In the absence of an HLA-matched family donor, early SCT from an unrelated donor will be the treatment of choice for most children. With clear evidence of a graft-versus-leukemia effect and a high post-transplant relapse rate, outcome of SCT will depend, in part, on the management of immunosuppression during the procedure. The impact of pretransplant cytoreductive treatment, such as intensive chemotherapy, splenectomy, or 13-cis retinoic acid, is unclear. Hypersensitivity for granulocyte-macrophage colony-stimulating factor and pathologic activation of the Ras/MAPK pathway play an important role in the pathophysiology of juvenile myelomonocytic leukemia and will provide the opportunity for several novel therapy approaches.
Similar content being viewed by others
References and Recommended Reading
Niemeyer CM, Aricò M, Basso G, et al.: Chronic myelomonocytic leukemia in childhood: a report of 110 cases. Blood 1997, 89:3534–3543. This report is a comprehensive description of clinical features of the largest series of patients with JMML.
Pinkel D: Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood 1998, 91:365–367.
Emanuel PD, Bates LJ, Castleberry RP, et al.: Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991, 77:925–929.
Flotho C, Valcamonica S, Mach-Pascual S, et al.: RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999, 13:32–37.
Side LE, Emanuel PD, Taylor B, et al.: Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998, 92:267–272.
Side L, Taylor B, Cayouette M, et al.: Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997, 336:1713–1720. This paper provides evidence that NF1 functions as a tumor suppressor gene in JMML and that neurofibromin is a regulator of Ras in early myelopoiesis.
Bollag G, Clapp DW, Shih S, et al.: Loss of NF1 results in activation of the RAS signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996, 12:144–148. This paper confirms the specific role of neurofibromin in negatively regulating GM-CSF signaling through Ras in hematopoietic cells.
Birnbaum RA, O’Marcaigh A, Wardak Z, et al.: NF1 and GM-CSF interact in myeloid leukemogenesis. Mol Cell 2000, 5:189–195.
Bader-Meunier B, Tchernia G, Mielot F, et al.: Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 1997, 130:885–889.
Tartaglia M, Niemeyer CM, Song X, et al.: Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia [abstract]. Blood 100:141a.
Steinherz PG, Exelby PR, Young J, et al.: Splenectomy after angiographic embolization of the splenic artery in patients with massive splenomegaly and severe thrombocytopenia in juvenile subacute myelomonocytic leukemia. Med Pediatr Oncol 1984, 12:28–32.
Lutz P, Zix-Kieffer I, Souillet G, et al.: Juvenile myelomonocytic leukemia: analyses of treatment results in the EORTC Childrens Leukemia Cooperative Group (CLCG). Bone Marrow Transplant 1996, 18:1111–1116.
Locatelli F, Niemeyer C, Angelucci E, et al.: Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. J Clin Oncol 1997, 15:566–573. An analysis of many children transplanted for JMML. This paper is a good review and interpretation of published results of SCT in patients with JMML.
Lilleyman JS, Harrison JF, Black JA: Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. Blood 1977, 49:559–562.
Castro-Malaspina H, Schaison G, Passe S, et al.: Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations and identification of prognostic factors. Cancer 1984, 54:675–686.
Laver J, Kushner BH, Steinherz PG: Juvenile chronic myeloid leukemia: therapeutic insights. Leukemia 1987, 1:730–733.
Chan HS, Estrov Z, Weitzman SS, et al.: The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. J Clin Oncol 1987, 5:1960–1967.
DeHeredia CD, Ortega JJ, Coll MT, et al.: Results of intensive chemotherapy in children with juvenile chronic myelomonocytic leukemia: a pilot study. Med Pediatr Oncol 1998, 31:516–520.
Woods WG, Barnard DR, Alonzo TA, et al.: Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children’s Cancer Group. J Clin Oncol 2002, 20:434–440.
Festa RS, Shende A, Lanzkowsky P: Juvenile chronic myelocytic leukemia: experience with intensive combination chemotherapy. Med Pediatr Oncol 1990, 18:311–316.
Hasle H, Kerndrup G, Yssing M, et al.: Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. Leukemia 1996, 10:1269–1273.
Mirro J, Dow LW, Kalwinsky DK, et al.: Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic leukemia. Cancer Treat Rep 1986, 70:363–367.
Hazani A, Barak Y, Berant M, et al.: Congenital juvenile chronic myelogenous leukemia: therapeutical trial with interferon alpha-2. Med Pediatr Oncol 1993, 21:73–76.
Suttorp M, Rister M, Schmitz N: Interferon-alpha-2 (IFN) plus hydroxyurea for treatment of juvenile chronic myelogenous leukemia. Med Pediatr Oncol 1994, 22:358–359.
Aricò M, Nespoli L, Caselli D, et al.: Juvenile chronic myeloid leukaemia and alpha-interferon. Eur J Pediatr 1989, 148:379–380.
Maybee D, Dubowy R, Krischer J, et al.: Unusual toxicity of high-dose alpha interferon (aIFN) in the treatment of juvenile chronic myelogenous leukemia (JCML) [abstract]. Proc Am Soc Clin Oncol 1992, 1:950a.
Castleberry RP, Emanuel PD, Zuckerman KS, et al.: A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994, 331:1680–1684.
Pui CH, Arico M: Isotretinoin for juvenile chronic myelogenous leukemia. N Engl J Med 1995, 332:1520–1521.
Castleberry RP, Chang M, Maybee D, et al.: A phase II study of 13-cis retinoic acid in juvenile myelomonocytic leukemia [abstract]. Blood 1997, 90:346a.
Matthes-Martin S, Mann G, Peters C, et al.: Allogeneic bone marrow transplantation for juvenile myelomonocytic leukaemia: a single centre experience and review of the literature. Bone Marrow Transplant 2000, 26:377–382. A good review and interpretation of published results of SCT in patients with JMML.
Manabe A, Okamura J, Yumura-Yagi K, et al.: Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group. Leukemia 2002, 16:645–649.
Sanders JE, Buckner CD, Thomas ED, et al.: Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. Blood 1988, 71:1144–1146.
Smith FO, King R, Nelson G, et al.: Unrelated donor bone marrow transplantation for children with juvenile myelomonocytic leukaemia. Br J Haematol 2002, 116:716–724. This paper describes the result of unrelated donor transplants in a registered population.
Worth A, Rao K, Webb D, et al.: Successful treatment of juvenile myelomonocytic leukemia relapsing post stem cell transplant using donor lymphocyte infusion. Blood 2003, 101:1713–1714.
Iversen PO, Turczynowicz S, Lewis J, et al.: A second generation GM-CSF analogue that prevents dissemination and induces remission of human juvenile myelomonocytic leukemia in engrafted immunodeficient mice. Blood 1997, 90:4910–4917.
Bernard F, Thomas C, Emile JF, et al.: Transient hematologic and clinical effect of E21R in a child with endstage juvenile myelomonocytic leukemia. Blood 2002, 99:2615–2616.
Frankel AE, Lilly M, Kreitman R, et al.: Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood 1998, 92:4279–4286.
Emanuel PD, Snyder RC, Wiley T, et al.: Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. Blood 2000, 95:639–645. This paper is an excellent summary of the pathophysiology of JMML.
Mahgoub N, Taylor BR, Gratiot M, et al.: In vitro and in vivo effects of a farnesyltransferase inhibitor on NF1-deficient hematopoietic cells. Blood 1999, 94:2469–2476.
Iversen PO, Emanuel PD, Sioud M: Targeting Raf-1 gene expression by a DNA enzyme inhibits juvenile myelomonocytic leukemia cell growth. Blood 2002, 99:4147–4153.
Iversen PO, Sorensen DR, Benestad HB: Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. Leukemia 2002, 16:376–381.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niemeyer, C.M., Kratz, C. Juvenile myelomonocytic leukemia. Curr. Treat. Options in Oncol. 4, 203–210 (2003). https://doi.org/10.1007/s11864-003-0021-z
Issue Date:
DOI: https://doi.org/10.1007/s11864-003-0021-z